FGR Diagnostic Criteria in Predicting Adverse Neonatal Outcomes

Accuracy of the Recent Consensus Based Definition of FGR Encompassing Biometric and Doppler Parameters in Predicting Adverse Neonatal Outcomes

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04933396

Enrollment

Registered

2021-06-21

Start date

2021-07-01

Completion date

2021-12-31

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

FGR

Brief summary

The purpose of this study is to evaluate using the recent consensus based definition for FGR using biometric and Doppler parameters to identify fetuses at risk of adverse perinatal outcomes compared to using solely biometric based parameter (EFW \<10th percentile according to the Hadlock growth standard).

Interventions

DIAGNOSTIC_TESTultrasound diagnostic criteria

evaluate using the recent consensus based definition for FGR using biometric and Doppler parameters to identify fetuses at risk of adverse perinatal outcomes compared to using solely biometric based parameter (EFW \<10th percentile according to the Hadlock growth standard).

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

* Participants included in this study will have the following criteria: * Pregnancies complicated with FGR (EFW \<10th percentile). * Singleton pregnancy.

Exclusion criteria

* • Fetal structural malformations or chromosomal abnormalities as detected by neonatal examination and anomaly scan during pregnancy. * Identified infectious etiologies detected during immediate postnatal examination or during pregnancy. * Gestational age cannot be calculated accurately. * Missing antenatal or perinatal outcome data.

Design outcomes

Primary

Measure	Time frame	Description
adverse events	30 days after delivery	neonatal outcome

Countries

Egypt

Contacts

Primary ContactRadwa Rasheedy, MD

radwaebed@yahoo.com01283492979

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026